Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3 deficient mice.

Tesch GH, Pullen N, Jesson MI, Schlerman FJ, Nikolic-Paterson DJ.

Am J Physiol Renal Physiol. 2019 Sep 30. doi: 10.1152/ajprenal.00340.2019. [Epub ahead of print]

PMID:
31566438
2.

The power of model-to-crop translation illustrated by reducing seed loss from pod shatter in oilseed rape.

Stephenson P, Stacey N, Brüser M, Pullen N, Ilyas M, O'Neill C, Wells R, Østergaard L.

Plant Reprod. 2019 Jun 20. doi: 10.1007/s00497-019-00374-9. [Epub ahead of print]

PMID:
31222677
3.

Nanoparticles and danger signals: Oral delivery vehicles as potential disruptors of intestinal barrier homeostasis.

Vita AA, Royse EA, Pullen NA.

J Leukoc Biol. 2019 Jul;106(1):95-103. doi: 10.1002/JLB.3MIR1118-414RR. Epub 2019 Mar 29. Review.

PMID:
30924969
4.

Growth rate regulation is associated with developmental modification of source efficiency.

Pullen N, Zhang N, Dobon Alonso A, Penfield S.

Nat Plants. 2019 Feb;5(2):148-152. doi: 10.1038/s41477-018-0357-9. Epub 2019 Feb 4.

PMID:
30718925
5.

Soluble transforming growth factor beta-1 enhances murine mast cell release of Interleukin 6 in IgE-independent and Interleukin 13 in IgE-dependent settings in vitro.

Lyons DO, Plewes MR, Pullen NA.

PLoS One. 2018 Nov 16;13(11):e0207704. doi: 10.1371/journal.pone.0207704. eCollection 2018.

6.

14-3-3 proteins activate Pseudomonas exotoxins-S and -T by chaperoning a hydrophobic surface.

Karlberg T, Hornyak P, Pinto AF, Milanova S, Ebrahimi M, Lindberg M, Püllen N, Nordström A, Löverli E, Caraballo R, Wong EV, Näreoja K, Thorsell AG, Elofsson M, De La Cruz EM, Björkegren C, Schüler H.

Nat Commun. 2018 Sep 17;9(1):3785. doi: 10.1038/s41467-018-06194-1.

7.

Spatio-temporal expression dynamics differ between homologues of flowering time genes in the allopolyploid Brassica napus.

Jones DM, Wells R, Pullen N, Trick M, Irwin JA, Morris RJ.

Plant J. 2018 Oct;96(1):103-118. doi: 10.1111/tpj.14020. Epub 2018 Aug 24.

8.

Enzymatic or In Vivo Installation of Propargyl Groups in Combination with Click Chemistry for the Enrichment and Detection of Methyltransferase Target Sites in RNA.

Hartstock K, Nilges BS, Ovcharenko A, Cornelissen NV, Püllen N, Lawrence-Dörner AM, Leidel SA, Rentmeister A.

Angew Chem Int Ed Engl. 2018 May 22;57(21):6342-6346. doi: 10.1002/anie.201800188. Epub 2018 Mar 22.

PMID:
29461645
9.

Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, Bonventre JV, Krolewski AS.

Kidney Int. 2018 May;93(5):1198-1206. doi: 10.1016/j.kint.2017.11.024. Epub 2018 Feb 2.

10.

Leaf-GP: an open and automated software application for measuring growth phenotypes for arabidopsis and wheat.

Zhou J, Applegate C, Alonso AD, Reynolds D, Orford S, Mackiewicz M, Griffiths S, Penfield S, Pullen N.

Plant Methods. 2017 Dec 22;13:117. doi: 10.1186/s13007-017-0266-3. eCollection 2017.

11.

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, Bonventre JV, Warram JH, Krolewski AS.

Kidney Int. 2017 Jul;92(1):258-266. doi: 10.1016/j.kint.2017.02.010. Epub 2017 Apr 7.

12.

Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease.

Sharif MN, Campanholle G, Nagiec EE, Wang J, Syed J, O'Neil SP, Zhan Y, Brenneman K, Homer B, Neubert H, Karim R, Pullen N, Evans SM, Fleming M, Chockalingam P, Lin LL.

PLoS One. 2016 May 12;11(5):e0155368. doi: 10.1371/journal.pone.0155368. eCollection 2016.

13.

Drug discovery in focal and segmental glomerulosclerosis.

Pullen N, Fornoni A.

Kidney Int. 2016 Jun;89(6):1211-20. doi: 10.1016/j.kint.2015.12.058. Epub 2016 Apr 23. Review.

14.

The relationship between the nucleolus and cancer: Current evidence and emerging paradigms.

Orsolic I, Jurada D, Pullen N, Oren M, Eliopoulos AG, Volarevic S.

Semin Cancer Biol. 2016 Jun;37-38:36-50. doi: 10.1016/j.semcancer.2015.12.004. Epub 2015 Dec 23. Review.

PMID:
26721423
15.

Bridging Translation by Improving Preclinical Study Design in AKI.

de Caestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, Askenazi D, Mour G, Harrell FE Jr, Pullen N, Okusa MD, Faubel S; ASN AKI Advisory Group.

J Am Soc Nephrol. 2015 Dec;26(12):2905-16. doi: 10.1681/ASN.2015070832. Epub 2015 Nov 4. Review.

16.

Incorporating prior knowledge improves detection of differences in bacterial growth rate.

Rickett LM, Pullen N, Hartley M, Zipfel C, Kamoun S, Baranyi J, Morris RJ.

BMC Syst Biol. 2015 Sep 21;9:60. doi: 10.1186/s12918-015-0204-9.

17.

Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β.

Kuai J, Mosyak L, Brooks J, Cain M, Carven GJ, Ogawa S, Ishino T, Tam M, Lavallie ER, Yang Z, Ponsel D, Rauchenberger R, Arch R, Pullen N.

Biochemistry. 2015 Mar 17;54(10):1918-29. doi: 10.1021/bi5015425. Epub 2015 Mar 6.

PMID:
25707433
18.

Inhibition of Thrombin-Activated Fibrinolysis Inhibitor Increases Survival in Experimental Kidney Fibrosis.

Atkinson JM, Pullen N, Da Silva-Lodge M, Williams L, Johnson TS.

J Am Soc Nephrol. 2015 Aug;26(8):1925-37. doi: 10.1681/ASN.2014030303. Epub 2014 Nov 19.

19.

ADAM10 is required for SCF-induced mast cell migration.

Faber TW, Pullen NA, Fernando JF, Kolawole EM, McLeod JJ, Taruselli M, Williams KL, Rivera KO, Barnstein BO, Conrad DH, Ryan JJ.

Cell Immunol. 2014 Jul;290(1):80-8. doi: 10.1016/j.cellimm.2014.05.005. Epub 2014 May 21.

20.

Bayesian model comparison and parameter inference in systems biology using nested sampling.

Pullen N, Morris RJ.

PLoS One. 2014 Feb 11;9(2):e88419. doi: 10.1371/journal.pone.0088419. eCollection 2014.

21.

Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses.

Morales JK, Saleem SJ, Martin RK, Saunders BL, Barnstein BO, Faber TW, Pullen NA, Kolawole EM, Brooks KB, Norton SK, Sturgill J, Graham L, Bear HD, Urban JF Jr, Lantz CS, Conrad DH, Ryan JJ.

J Leukoc Biol. 2014 Apr;95(4):643-50. doi: 10.1189/jlb.0913510. Epub 2013 Dec 12.

22.

Genotype-dependent effects of TGF-β1 on mast cell function: targeting the Stat5 pathway.

Fernando J, Faber TW, Pullen NA, Falanga YT, Kolawole EM, Oskeritzian CA, Barnstein BO, Bandara G, Li G, Schwartz LB, Spiegel S, Straus DB, Conrad DH, Bunting KD, Ryan JJ.

J Immunol. 2013 Nov 1;191(9):4505-13. doi: 10.4049/jimmunol.1202723. Epub 2013 Sep 25.

23.

Simple network motifs can capture key characteristics of the floral transition in Arabidopsis.

Pullen N, Jaeger KE, Wigge PA, Morris RJ.

Plant Signal Behav. 2013 Nov;8(11):e26149. doi: 10.4161/psb.26149. Epub 2013 Aug 29.

24.

Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function.

Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA.

Diabetes. 2013 Aug;62(8):2870-8. doi: 10.2337/db12-1619. Epub 2013 Jul 8.

25.

Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells.

Kay LJ, Gilbert M, Pullen N, Skerratt S, Farrington J, Seward EP, Peachell PT.

Clin Exp Allergy. 2013 Jul;43(7):741-51. doi: 10.1111/cea.12142.

PMID:
23786281
26.

Interlocking feedback loops govern the dynamic behavior of the floral transition in Arabidopsis.

Jaeger KE, Pullen N, Lamzin S, Morris RJ, Wigge PA.

Plant Cell. 2013 Mar;25(3):820-33. doi: 10.1105/tpc.113.109355. Epub 2013 Mar 29.

27.

Macrophage functional polarization (M1/M2) in response to varying fiber and pore dimensions of electrospun scaffolds.

Garg K, Pullen NA, Oskeritzian CA, Ryan JJ, Bowlin GL.

Biomaterials. 2013 Jun;34(18):4439-51. doi: 10.1016/j.biomaterials.2013.02.065. Epub 2013 Mar 17.

28.

An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion.

Atkinson JM, Pullen N, Johnson TS.

Matrix Biol. 2013 Jun 24;32(5):277-87. doi: 10.1016/j.matbio.2013.01.006. Epub 2013 Jan 29.

PMID:
23369837
29.

Domain 1 of mucosal addressin cell adhesion molecule has an I1-set fold and a flexible integrin-binding loop.

Yu Y, Zhu J, Huang PS, Wang JH, Pullen N, Springer TA.

J Biol Chem. 2013 Mar 1;288(9):6284-94. doi: 10.1074/jbc.M112.413153. Epub 2013 Jan 7.

30.

Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor.

Birrell MA, Maher SA, Buckley J, Dale N, Bonvini S, Raemdonck K, Pullen N, Giembycz MA, Belvisi MG.

Br J Pharmacol. 2013 Jan;168(1):129-38. doi: 10.1111/j.1476-5381.2012.02088.x.

31.

The Fyn-STAT5 Pathway: A New Frontier in IgE- and IgG-Mediated Mast Cell Signaling.

Pullen NA, Falanga YT, Morales JK, Ryan JJ.

Front Immunol. 2012 May 11;3:117. doi: 10.3389/fimmu.2012.00117. eCollection 2012.

32.

Prostaglandin E2 stimulates cystogenesis through EP4 receptor in IMCD-3 cells.

Elberg D, Turman MA, Pullen N, Elberg G.

Prostaglandins Other Lipid Mediat. 2012 May;98(1-2):11-6. doi: 10.1016/j.prostaglandins.2012.03.005. Epub 2012 Apr 6.

PMID:
22503965
33.

Lyn but not Fyn kinase controls IgG-mediated systemic anaphylaxis.

Falanga YT, Chaimowitz NS, Charles N, Finkelman FD, Pullen NA, Barbour S, Dholaria K, Faber T, Kolawole M, Huang B, Odom S, Rivera J, Carlyon J, Conrad DH, Spiegel S, Oskeritzian CA, Ryan JJ.

J Immunol. 2012 May 1;188(9):4360-8. doi: 10.4049/jimmunol.1003223. Epub 2012 Mar 26.

34.

Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.

Pullen NA, Barnstein BO, Falanga YT, Wang Z, Suzuki R, Tamang TD, Khurana MC, Harry EA, Draber P, Bunting KD, Mizuno K, Wilson BS, Ryan JJ.

J Biol Chem. 2012 Jan 13;287(3):2045-54. doi: 10.1074/jbc.M111.311142. Epub 2011 Nov 30.

35.

The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.

Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Maggie Dempster A, de Haan L, Jones K, Pullen N, de Boer AS, Sims J, Ian Ragan C.

Regul Toxicol Pharmacol. 2012 Mar;62(2):347-54. doi: 10.1016/j.yrtph.2011.10.016. Epub 2011 Nov 6.

PMID:
22100994
36.

In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).

Russell R, Doyle R, Turner J, Attkins N, Ramsey S, Weibley L, Bateman L, Bictash M, Neal-Morgan S, Ivarsson M, Pullen N.

Eur J Pharmacol. 2011 Nov 30;670(2-3):347-55. doi: 10.1016/j.ejphar.2011.09.034. Epub 2011 Sep 21.

PMID:
21958878
37.

Platinum anticancer agents and antidepressants: desipramine enhances platinum-based cytotoxicity in human colon cancer cells.

Kabolizadeh P, Engelmann BJ, Pullen N, Stewart JK, Ryan JJ, Farrell NP.

J Biol Inorg Chem. 2012 Jan;17(1):123-32. doi: 10.1007/s00775-011-0836-1. Epub 2011 Sep 15.

38.

Sulfonamides as selective oestrogen receptor β agonists.

Roberts LR, Armor D, Barker C, Bent A, Bess K, Brown A, Favor DA, Ellis D, Irving SL, MacKenny M, Phillips C, Pullen N, Stennett A, Strand L, Styles M.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5680-3. doi: 10.1016/j.bmcl.2011.08.041. Epub 2011 Aug 16.

PMID:
21885279
39.

Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma.

Pullen NA, Anand M, Cooper PS, Fillmore HL.

J Neurooncol. 2012 Feb;106(3):461-71. doi: 10.1007/s11060-011-0691-5. Epub 2011 Aug 21.

PMID:
21858729
40.

The translational efficacy of a nonsteroidal progesterone receptor antagonist, 4-[3-cyclopropyl-1-(mesylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy,-2,6-dimethylbenzonitrile (PF-02413873), on endometrial growth in macaque and human.

Howe DC, Mount NM, Bess K, Brown A, Bungay P, Gibson KR, Hawcock T, Richard J, Jones G, Walley R, McLeod A, Apfeldorfer C, Ramsey S, Tweedy S, Pullen N.

J Pharmacol Exp Ther. 2011 Nov;339(2):642-53. doi: 10.1124/jpet.111.183848. Epub 2011 Aug 17.

PMID:
21849626
41.

Cellular exchange in an endometriosis-adhesion model using GFP transgenic mice.

Wilkosz S, Pullen N, de-Giorgio-Miller A, Ireland G, Herrick S.

Gynecol Obstet Invest. 2011;72(2):90-7. doi: 10.1159/000325826. Epub 2011 Jul 20.

PMID:
21778678
42.

The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies.

Pullen N, Birch CL, Douglas GJ, Hussain Q, Pruimboom-Brees I, Walley RJ.

Hum Reprod Update. 2011 Nov-Dec;17(6):791-802. doi: 10.1093/humupd/dmr030. Epub 2011 Jul 6. Review.

PMID:
21733981
43.

In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ receptor antagonist.

af Forselles KJ, Root J, Clarke T, Davey D, Aughton K, Dack K, Pullen N.

Br J Pharmacol. 2011 Dec;164(7):1847-56. doi: 10.1111/j.1476-5381.2011.01495.x. Erratum in: Br J Pharmacol. 2012 Jun;166(3):1192. Dosage error in article text.

44.

Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity.

Liaskou E, Karikoski M, Reynolds GM, Lalor PF, Weston CJ, Pullen N, Salmi M, Jalkanen S, Adams DH.

Hepatology. 2011 Feb;53(2):661-72. doi: 10.1002/hep.24085. Epub 2011 Jan 10.

45.

The future of non-human primate use in mAb development.

Chapman KL, Pullen N, Andrews L, Ragan I.

Drug Discov Today. 2010 Mar;15(5-6):235-42. doi: 10.1016/j.drudis.2010.01.002. Epub 2010 Jan 21. Review.

PMID:
20096369
46.

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.

Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V.

MAbs. 2009 Sep-Oct;1(5):505-16. Epub 2009 Sep 30.

47.

CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis.

Allavena R, Noy S, Andrews M, Pullen N.

Am J Pathol. 2010 Feb;176(2):556-62. doi: 10.2353/ajpath.2010.090437. Epub 2009 Dec 24.

48.

Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide.

Pullen NA, Fillmore HL.

J Neurooncol. 2010 Jan;96(2):201-9. doi: 10.1007/s11060-009-9965-6. Epub 2009 Jul 21.

PMID:
19629394
49.

Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody.

Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Finco-Kent D, Reagan W, Zhao S, Kawabata T, Sreckovic S.

Br J Pharmacol. 2009 May;157(2):281-93. doi: 10.1111/j.1476-5381.2009.00137.x. Epub 2009 Apr 2.

50.

The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease.

Rife T, Rasoul B, Pullen N, Mitchell D, Grathwol K, Kurth J.

J Neurosci Res. 2009 Aug 1;87(10):2319-25. doi: 10.1002/jnr.22045.

PMID:
19326438

Supplemental Content

Loading ...
Support Center